ClinicalTrials.gg
RecruitingNCT06428669Updated Jun 6, 2024

Effect of Nitropaste in Chest Masculinizing Surgery

A Phase 4 interventional study of Nitro-Bid 2 % Topical Ointment in Gender Dysphoria, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-06.

Sponsored by University of Virginia · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 9 months after the study started (first participant enrolled Aug 2022, registered May 2024).
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Gender Dysphoria with a site in United States — 11 open to participants now, 13 under way, 3 of them phase 3. Gender Dysphoria · United States.

Planned enrollment
4th of 15
256 · median 50
Started
2022
with 4 others
Phase 4
4 of 31
1 open now
Primary completion
2025-08
later than 0 of 12 live
Registered
23rd of 31
by date

Among the 31 studies in Gender Dysphoria with a site in United States, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2022, is one of 4 in phase 4, reaches primary completion later than 0 of the 12 other live ones, and was the 23rd registered.

Gender Dysphoria

85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.

Browse Gender Dysphoria studies →

Open to participants now

11 of the 31 studies in Gender Dysphoria with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gender Dysphoria studies recruiting now, 15 (48%) set no upper age limit and 10 (32%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Gender Dysphoria with a site in United States, or all of them as a file.
02

Study summary

Nitropaste is a topical agent that contains 2% nitroglycerin. It is an effective vascular smooth dilator, with more powerful effect on venous vasculature than arterial vasculature. While its main indication is for angina pectoris, there have been many studies showing improved survival of axial and random pattern flaps. Furthermore, recent clinical studies highlight significantly decreased mastectomy flap wound complication and need for sharp debridement. Nitropaste has low rates of side effects and is very well tolerated in general. To this date, there's no study that investigates its utility on patients who are undergoing chest masculinizing surgery. The purpose of this study is to investigate the potential utility of nitropaste in reducing rates of wound complications in patients undergoing chest masculinizing surgery.

Read the detailed description

Nitropaste is a topical agent that contains 2% nitroglycerin. It is an effective vascular smooth dilator, with more powerful effect on venous vasculature than arterial vasculature. While its main indication is for angina pectoris, there have been many studies showing improved survival of axial and random pattern flaps. Furthermore, recent clinical studies highlight significantly decreased mastectomy flap wound complication and need for sharp debridement. Nitropaste has low rates of side effects and is very well tolerated in general. To this date, there's no study that investigates its utility on patients who are undergoing chest masculinizing surgery. The purpose of this study is to investigate the potential utility of nitropaste in reducing rates of wound complications in patients undergoing chest masculinizing surgery utilizing double incision with free nipple grafting technique. The investigators will conduct a prospective, randomized, single-blinded study and compare nitropaste vs. no nitropaste on mastectomy flaps. Nitropaste will be applied intraoperatively and the patients will not have to re-apply it. Follow up will occur on post-op day 5, 2 weeks, and 6 weeks during their routine postop visits. A study coordinator will document the condition of free nipple grafts and any other wounds at surgical site if present, which will be the primary outcome. Any complications including hematoma, seroma, infection, hypertrophic scarring, need for sharp debridement, 30 day ED visit or admission rates will be documented as secondary outcome.

03

Conditions studied

  • Gender Dysphoria

Browse trials for

Keywords

  • Gender affirming surgery
  • Chest masculinizing Surgery
  • Nitropaste
  • Wound healing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any adult (18 or older) patients of any gender identity who are undergoing chest masculinizing surgery with double incision and free nipple grafting.

Exclusion criteria

Exclusion Criteria:

  • Minor patients (younger than 18)
  • Anyone who's not getting free nipple grafting
  • Anyone who's not utilizing double incision pattern
  • Prisoners, anyone who is allergic to nitropaste
  • Anyone who is taking phosphodiesterase inhibitor (ex)Sildenafil, tadalafil, vardenafil)
  • Anyone who's taking soluble guanylate cyclase stimulator riociguatdz
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
256 participants (estimated)

Study arms

  • No intervention
    No nitropaste group

    Participants get standard of care chest masculinizing surgery utilizing double incision and free nipple grafting surgery. They will get standard dressing applied, which includes Xeroform bolster over the nipple grafts + Tegederm over the bolster and surgical site and instructed not to remove the dressing until they come to clinic on POD5 for bolster take down.

  • Experimental
    Nitropaste group

    Participants get standard of care chest masculinizing surgery utilizing double incision and free nipple grafting surgery. They will then get 2 packets of nitropaste applied (1 on each chest) around the free nipple graft and surgical sites. They will then get standard dressing applied, which includes Xeroform bolster over the nipple grafts + Tegederm over the bolster and surgical site and instructed not to remove the dressing until they come to clinic on POD5 for bolster take down.

    Drug: Nitro-Bid 2 % Topical Ointment

Interventions

  • DrugNitroglycerinStudies of NitroglycerinNitroglycerin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intervention group will get 30mg of Nitro-Bid topical ointment applied over the chest (15mg/ 1 packet on each side) one time intra-operatively

06

What researchers measure

Primary outcomes

  1. Free Nipple Graft Take

    Rate of partial nipple graft loss (0-50%, 50% or more) or Complete nipple graft loss

    Time frame: Will be assessed at 5 days, 2 weeks, 6 weeks post-op

  2. Wounds

    Rate of superficial wound, deep wound, delayed wound healing

    Time frame: Will be assessed at 5 days, 2 weeks, 6 weeks post-op

Secondary outcomes

  1. Complications

    hematoma, seroma, infection, hypertrophic scarring

    Time frame: Will be tracked up until 3 months post-op

  2. Sharp debridement

    Need for any sharp debridement (office or OR)

    Time frame: Will be tracked up until 3 months post-op

  3. Revision

    Need for any revision

    Time frame: Will be tracked up until 3 months post-op

  4. Readmission

    30 day ED or inpatient admission rate

    Time frame: Will be tracked 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Aug 2025, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2024
First posted
May 24, 2024
StartActual
Aug 15, 2022
Primary completionEst.
Aug 2025
CompletionEst.
Nov 2025
Last update
Jun 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06428669
Responsible party
John Stranix (Assistant Professor, Department of Plastic Surgery, University of Virginia) — Principal investigator
First posted
May 24, 2024
Start date
Aug 15, 2022
Primary completion
Aug 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Jun 6, 2024

Study contacts

Rachel H Park, MD
Contact
rhp7gu@hscmail.mcc.virginia.edu
434-327-2140
John T Stranix, MD
principal investigator · UVA

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion